-
1.
The Effect of Vitamin D3 Supplementation on Physical Capacity among Active College-Aged Males.
Kujach, S, Lyzwinski, D, Chroboczek, M, Bialowas, D, Antosiewicz, J, Laskowski, R
Nutrients. 2020;(7)
Abstract
Vitamin D3 supplementation can affect strength and power; however, the effect on both aerobic and anaerobic performance remains unclear. Here, we investigate the effects of eight weeks of a high dose of vitamin D3 supplementation and its impact on circulating 25-hydroxyvitamin D (25-OH-D3) concentrations and selected indicators of physical capacity. Subjects (n = 28, age 21.1 ± 1.6) were divided into two groups: supplemented (SUP), which was given 6000 IU of vitamin D3 daily for eight weeks; and placebo group (PLA). Serum 25-OH-D3 concentrations were determined in pre- and post-intervention. Aerobic (VO2max test) and anaerobic (Wingate Anaerobic Test) capacity were determined before and after the supplementation. The mean baseline concentration of 25-OH-D3 was recognized as deficient (20 ng/mL) and significantly increased over time in the supplemented group (p < 0.01, η2 = 0.86), whilst it remained unchanged in the placebo group. Moreover, the supplementation caused a significant improvement in maximal aerobic (p < 0.05, η2 = 0.27) and anaerobic power (p < 0.01, η2 = 0.51) whereas no changes were observed in PLA group. The VO2max differences were also significant in the supplemented group (p < 0.05). In summary, the changes in aerobic and anaerobic capacity observed in this study were associated with a serum concentration of 25-OH-D3. Our data imply that vitamin D3 supplementation with a dose of 6000 IU daily for eight weeks is sufficient to improve physical capacity and vitamin D3 status.
-
2.
Self-Directed Oral Vitamin D Supplementation in Professional Ballet Dancers: A Randomized Controlled Trial Pilot Study.
Rowan, FE, Benjamin-Laing, H, Kennedy, A, De Medici, A, Beasley, I, Haddad, FS
Journal of dance medicine & science : official publication of the International Association for Dance Medicine & Science. 2019;(3):91-96
Abstract
Inadequate levels of vitamin D may lead to poor performance in professional dancers. Therefore, dietary supplementation may be essential in this population. This longitudinal pilot study to a randomized controlled trial assessed dancer compliance with self-directed oral vitamin D supplementation. Seventy-one dancers, 41 females and 30 males with a mean age of 31.1 years, were recruited from The Royal Ballet, London. Baseline serum 25(OH)D levels were measured and dancers were interviewed, examined, and provided with oral supplements for the winter period, November 2011 to March 2012. Dancers with normal serum 25(OH)D levels were provided with maintenance supplements (1,000 IU/ day) and those with insufficient or deficient serum 25(OH)D levels were given a loading dose of 60,000 IU weekly for 2 and 6 weeks, respectively. Serum 25(OH) D levels were measured at 1 and 2 years and dancers were sampled for compliance with instructions. Mean compliance during loading and maintenance was 86% and 50%, respectively. Mean serum 25(OH)D levels at start and end of the study period were 79.3 ± 31.6 nmol/L and 78.68 ± 19.8 nmol/L, respectively. Only one-third of dancers with insufficient (N = 5) and deficient (N = 5) serum vitamin D levels improved to normal values. It is concluded that professional ballet dancers demonstrate good compliance with self-directed loading doses of vitamin D supplementation but poor compliance with maintenance doses. Poor maintenance compliance may have accounted for the low rates of serum vitamin D level improvement among dancers with insufficient or deficient levels.
-
3.
The effect of cholecalciferol for lowering albuminuria in chronic kidney disease: a prospective controlled study.
Molina, P, Górriz, JL, Molina, MD, Peris, A, Beltrán, S, Kanter, J, Escudero, V, Romero, R, Pallardó, LM
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2014;(1):97-109
Abstract
BACKGROUND Growing evidence indicates that vitamin D receptor activation may have antiproteinuric effects. We aimed to evaluate whether vitamin D supplementation with daily cholecalciferol could reduce albuminuria in proteinuric chronic kidney disease (CKD) patients. METHODS This 6-month prospective, controlled, intervention study enrolled 101 non-dialysis CKD patients with albuminuria. Patients with low 25(OH) vitamin D [25(OH)D] and high parathyroid hormone (PTH) levels (n = 50; 49%) received oral cholecalciferol (666 IU/day), whereas those without hyperparathyroidism (n = 51; 51%), independent of their vitamin D status, did not receive any cholecalciferol, and were considered as the control group. RESULTS Cholecalciferol administration led to a rise in mean 25(OH)D levels by 53.0 ± 41.6% (P < 0.001). Urinary albumin-to-creatinine ratio (uACR) decreased from (geometric mean with 95% confidence interval) 284 (189-425) to 167 mg/g (105-266) at 6 months (P < 0.001) in the cholecalciferol group, and there was no change in the control group. Reduction in a uACR was observed in the absence of significant changes in other factors, which could affect proteinuria, like weight, blood pressure (BP) levels or antihypertensive treatment. Six-month changes in 25(OH)D levels were significantly and inversely associated with that in the uACR (Pearson's R = -0.519; P = 0.036), after adjustment by age, sex, body mass index, BP, glomerular filtration rate and antiproteinuric treatment. The mean PTH decreased by -13.8 ± 20.3% (P = 0.039) only in treated patients, with a mild rise in phosphate and calcium-phosphate product [7.0 ± 14.7% (P = 0.002) and 7.2 ± 15.2% (P = 0.003), respectively]. CONCLUSIONS In addition to improving hyperparathyroidism, vitamin D supplementation with daily cholecalciferol had a beneficial effect in decreasing albuminuria with potential effects on delaying the progression of CKD.
-
4.
[Serum levels of 25(OH)D3 in patients with prostate cancer compared to healthy men].
Lizis-Kolus, K, Hubalewska-Dydejczyk, A, Piwońska-Solska, B, Sowa-Staszczak, A, Kowalska, A, Jaskulski, J, Obarzanowski, M, Orlowski, P
Przeglad lekarski. 2013;(11):926-32
Abstract
UNLABELLED Prostate cancer (CaP) is one of the most common cancers in men. On the basis of international and Polish epidemiological data it is estimated that is the second leading cause of death from cancer. These data tend to look for underlying causes such a high incidence. Detected in 1990, the relationship between UV radiation and the reduction of mortality rate due to CaP gave rise to the search for effects of vitamin D, in CaP. The aim of this study was to evalu ate the concentration of 25(OH)D3 in patients treated for prostate cancer (CaP) compared to the control group of healthy men, and attempt to assess the relationship 25(OH)D3 shortage of CaP incidence and degree of its clinical advancement. MATERIAL AND METHODS The study included 42 men, aged from 42 to 86 years (average age 66.14+/-8.92 years) treated between 2005-2013 in śCO due to prostate cancer. The control group consisted of 40 healthy men aged from 42 to 78 years (average age 63.17+/-9.02) in whom CaP and other cancer disease were excluded. Patients treated for CaP were divid ed into two groups depending on the severity of the cancer being evaluated by the TNM scale. Group 1 consisted of 11 patients with low severity of CaP-T1, group 2 -31 patients with higher tumor stage (T2+T3+T4). In all patients, serum 25(OH)D3 was marked in venous blood collected in the morning. RESULTS The concentration of 25(OH)D3 in the group of patients with CaP occured in 80.94. There was no statistically significant difference between patients 25(OH)D3 concentra tions of CaP and control group (p = 0.3756). In both subgroups of patients with CaP showed no statistically significant difference 25(OH)D3 concentra tions (p = 0.5672), depending on the tumor advancement stage (according to TNM). CONCLUSIONS The majority of tested patients with prostate cancer were low concentrations of vitamin D3. There were no significant differences in concentrations of vitamin D3 in the group of patients with CaP and in the control group. Based on the analysis no relationship between the 25(OH)D3 concentration and the stage of CaP was showed, too.
-
5.
Vitamin D supplementation in patients with diabetes mellitus type 2 on different therapeutic regimens: a one-year prospective study.
Alkharfy, KM, Al-Daghri, NM, Sabico, SB, Al-Othman, A, Moharram, O, Alokail, MS, Al-Saleh, Y, Kumar, S, Chrousos, GP
Cardiovascular diabetology. 2013;:113
Abstract
BACKGROUND Little or no research has determined the effect of vitamin D3 supplementation in conjunction with pharmacological and non-pharmacological approaches in the diabetes mellitus type 2 (DMT2) patients. The objective of this study was to determine the effect of vitamin D3 supplementation in a cohort of Saudi DMT2 population on diet, insulin and/or different oral hypoglycemic agents and compare them with a non-DMT2 control cohort. METHODS A total of 499 randomly selected Saudi subjects divided into 8 groups [Non-DMT2 Control = 151; Rosiglitazone alone = 49; Diet = 15; Insulin alone = 55; Insulin + Orals = 12; Metformin alone = 121; Oral agents combination = 37; Sulphonylurea alone = 59] were included in this 12-month interventional study. All DMT2 patients were given 2000 IU vitamin D3 daily, while the control group received none but were advised to increase sun exposure. Anthropometrics, glucose, lipid profile and 25-hydroxyvitamin D (25-OHVitD) were measured at baseline, 6 and 12 months. RESULTS Circulating 25-OHVitD concentrations improved in all patient groups. The metformin group showed the highest change in circulating vitamin D levels both at 6 months (62.6%) and 12 months (50.6%) as compared to baseline (p < 0.001). No significant changes were observed in the BMI and glucose in any of the DMT2 groups. In contrast, the insulin + oral agents group showed more significant improvements in the metabolic profile, which included triglycerides and total cholesterol, as well as systolic blood pressure and HDL-cholesterol in males. Also, significant decreases in triglycerides were observed in the rosiglitazone and insulin + oral hypoglycemic agent groups both at 6 and 12 months of supplementation (both p-values <0.001). CONCLUSION While in all DMT2 groups circulating levels of 25-OHVitD increased after supplementation, in DMT2 patients on insulin in combination with other drugs benefitted the most in improving cardiovascular risk. Metformin improves 25-hydroxyvitamin D levels but did not seem to confer other added cardiometabolic benefits.
-
6.
Effect of 1 year B and D vitamin supplementation on LINE-1 repetitive element methylation in older subjects.
Hübner, U, Geisel, J, Kirsch, SH, Kruse, V, Bodis, M, Klein, C, Herrmann, W, Obeid, R
Clinical chemistry and laboratory medicine. 2013;(3):649-55
Abstract
BACKGROUND Disturbed DNA methylation is causally related to chronic diseases like cancer and atherosclerosis. B vitamins are cofactors required for methyl group synthesis and may therefore affect DNA methylation. Vitamin D has epigenetic effects. We tested if B and D vitamin supplementation has an effect on genomic long interspersed nuclear element-1 (LINE-1) methylation and the metabolites S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH). METHODS Fifty subjects (median age 68.0 years) were supplemented with a daily oral dose of B vitamins (500 µg folic acid, 500 µg vitamin B12 and 50 mg vitamin B6), 1200 IU vitamin D and 456 mg calcium. Fasting blood samples were collected before and after 1 year of supplementation. LINE-1 methylation was determined in genomic DNA from blood cells as a surrogate for whole genome methylation. In addition, SAM, SAH and total homocysteine (tHcy) were measured in plasma samples. RESULTS Plasma homocysteine decreased significantly after supplementation (12.8 vs. 9.1 µmol/L; p<0.05), whereas SAM, SAH, the SAM/SAH ratio and LINE-1 methylation did not change significantly. LINE-1 methylation was not significantly correlated with SAH, homocysteine or B vitamins. CONCLUSIONS Long-term vitamin B supplementation had no effect on LINE-1 methylation in blood cells nor on plasma levels of SAM and SAH. Vitamin B and D supplementation seems to have no effect on DNA methylation, especially in cases where no severe deficiency exists.
-
7.
Serum 25(OH)D3 vitamin status of elderly Finnish women is suboptimal even after summer sunshine but is not associated with bone density or turnover.
Pekkarinen, T, Turpeinen, U, Hämäläinen, E, Löyttyniemi, E, Alfthan, H, Välimäki, MJ
European journal of endocrinology. 2010;(1):183-9
Abstract
OBJECTIVE Concentrations of 50 and 75 nmol/l are proposed as serum 25-hydroxyvitamin D (25(OH)D) target for older people from the view of bone health. We evaluated vitamin D status of elderly Finnish women in light of these definitions, its relationship to bone mineral density (BMD) and turnover, and improvement by summer sunshine. DESIGN Population-based study. METHODS A total of 1604 ambulatory women aged 62-79 years were studied; 66% used vitamin D supplements. Serum 25(OH)D(3) was measured with HPLC before and after summer, and heel BMD in spring. In subgroups, serum parathyroid hormone (PTH) and type I procollagen aminoterminal propeptide (PINP) were analyzed. RESULTS In spring, 60.3% of the women had 25(OH)D(3) CONCLUSIONS Vitamin D status of elderly Finnish women is suboptimal if 25(OH)D(3) levels of 50 or 75 nmol/l are used as a threshold. It is moderately increased by supplement intake and summer sunshine. However, 25(OH)D(3) concentrations did not influence bone density in terms of serum PINP and bone turnover rate.
-
8.
Prophylaxis against bone loss in Kock reservoir patients with reduced glomerular filtration rate.
Jonsson, O, Herlitz, H, Lindholm, E, Lindstedt, G, Pazooki, D, Törnqvist, H, Mellström, D
Scandinavian journal of urology and nephrology. 2005;(3):200-5
Abstract
OBJECTIVE We investigated whether treatment with calcium carbonate and vitamin D3 can improve the bone mineral content of patients with ileal reservoirs for continent urinary diversion and a reduced glomerular filtration rate (GFR). MATERIAL AND METHODS Twenty-six patients with Kock reservoirs were included in the study. Bone mineralization was determined using dual-energy X-ray absorptiometry. Kidney function was estimated from Cr-EDTA clearance and serum cystatin C concentration. Osteocalcin and parathyroid hormone in serum were also measured. Patients with reduced GFR were treated with calcium carbonate and vitamin D3 perorally. RESULTS Bone mineral density in the femur neck and hip increased in the treatment group, as reflected by an improved T score. CONCLUSION Patients with ileal reservoirs for continent urinary diversion and reduced kidney function should be supplemented with calcium carbonate and vitamin D3 in order to reduce the long-term risk of osteoporosis.